Journal of Neural Transmission

, Volume 114, Issue 5, pp 621–628 | Cite as

Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations

  • M. Bibl
  • B. Mollenhauer
  • S. Wolf
  • H. Esselmann
  • P. Lewczuk
  • J. Kornhuber
  • J. Wiltfang
Article

Summary.

Cerebrospinal fluid (CSF) carboxyterminally truncated amyloid-beta (Aβ) peptides, Aβ1-42 and tau protein were evaluated in 30 patients with frontotemporal lobe degenerations (FTLD), 30 Alzheimer’s disease (AD) patients and 30 non-demented disease controls (NDC) by Aβ-SDS-PAGE/immunoblot as well as commercial ELISAs for Aβ1-42 and total tau. FTLD displayed a significant drop of Aβ1-37 (p = 2.7 × 10−4), Aβ1-38 (p = 4.2 × 10−5) and Aβ1-42 (p = 3.3 × 10−4). Aβ1-42 was selectively decreased in AD (p = 8.5 × 10−10). Decreased Aβ1-38 enabled contrasts of beyond 85% to distinguish FTLD from AD and NDC patients, alone or in combination. Accordingly, low CSF Aβ1-37 and Aβ1-38 represent a biomarker candidate for FTLD and may reflect disease-specific changes of APP metabolism. Further validation should be carried out on dementias other than AD, diagnostically relevant control groups without dementia and without any evident affection of the central nervous system and subgroups of FTLD. Moreover, independent methods of measurement should be applied to CSF Aβ1-38.

Keywords: Alzheimer’s disease, frontotemporal degeneration, cerebrospinal fluid, amyloid-β peptides, biomarkers 

Abbreviations:

Aβ peptides

Amyloid-beta peptides

Aβ-SDS-PAGE/immunoblot

amyloid-beta-sodium-dodecyl-sulphate-polyacrylamide-gel-electrophoresis with western immunoblot

AD

Alzheimer’s disease

APP

beta-amyloid precursor protein

bicine

N,N′-bis-[2-hydroxyethyl]glycine

%C

percentage of N,N′-bis-acrylamide

CCD-camera

charge coupled device camera

CSF

cerebrospinal fluid

Ct-elongated

carboxyterminally elongated

Ct-truncated

carboxyterminally truncated

ECL

enhanced chemiluminescence

ELISA

Enzyme Linked Immunosorbent Assay

FTLD

frontotemporal lobe degenerations

MMSE

Mini-Mental-Status Examination

NDC

non-demented disease controls

NINCDS-ADRDA

National Institute Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association

SDS

sodium dodecyl sulphate

%T

percentage of acrylamide

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen, C, Jensen, M, Lannfelt, L, Lindau, M, Wahlund, LO 2000Amyloid Aβ40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementiaNeuroreport11287290PubMedCrossRefGoogle Scholar
  2. Andreasen, N, Minthon, L, Davidsson, P, Vanmechelen, E, Vanderstichele, H, Winblad, B, Blennow, K 2001Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practiceArch Neurol58373379PubMedCrossRefGoogle Scholar
  3. Arnold, SE, Han, LY, Clark, CM, Grossman, M, Trojanowski, JQ 2000Quantitative neurohistological features of frontotemporal degenerationJ Struct Biol130271279CrossRefGoogle Scholar
  4. Bibl, M, Esselmann, H, Otto, M, Lewczuk, P, Cepek, L, Rüther, E, Kornhuber, J, Wiltfang, J 2004Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer’s disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of Aβ peptidesElectrophoresis2529122918PubMedCrossRefGoogle Scholar
  5. Bibl, M, Mollenhauer, B, Esselmann, H, Klafki, HW, Sparbier, K, Smirnov, A, Cepek, L, Lewczuk, P, Trenkwalder, C, Rüther, E, Kornhuber, J, Otto, M, Wiltfang, J 2006aCSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementiaBrain12911771187CrossRefGoogle Scholar
  6. Bibl, M, Mollenhauer, B, Esselmann, H, Lewczuk, P, Trenkwalder, C, Brechlin, P, Rüther, E, Kornhuber, J, Otto, M, Wiltfang, J 2006bCSF diagnosis of Alzheimer’s disease and dementia with Lewy bodiesJ Neural Transm11317711778CrossRefGoogle Scholar
  7. Blennow, K 2004Cerebrospinal fluid protein biomarkers for Alzheimer’s diseaseNeuroRx1213225PubMedCrossRefGoogle Scholar
  8. Blennow, K, Wallin, A, Agren, H, Spenger, C, Siegfried, J, Vanmechelen, E 1995Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer’s diseaseMol Chem Neuropathol26231245PubMedCrossRefGoogle Scholar
  9. Citron, M, Diehl, TS, Gordon, G, Biere, AL, Seubert, P, Selkoe, DJ 1996Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activitiesProc Natl Acad Sci USA931317013175PubMedCrossRefGoogle Scholar
  10. Dermaut, B, Kumar-Singh, S, Engelborghs, S, Theuns, J, Rademakers, R, Saerens, J, Pickut, BA, Peeters, K, van der Broeck, M, Vennekens, K, Claes, S, Cruts, M, Cras, P, Martin, JJ, Van Broeckhoven, C, De Deyn, PP 2004A novel presenilin 1 mutation associated with Pick’s disease but not β-amyloid plaquesAnn Neurol55617626PubMedCrossRefGoogle Scholar
  11. Galasko, D, Marder, K 2002Picking away at frontotemporal dementiaNeurology5815851586PubMedGoogle Scholar
  12. Glenner, GG, Wong, CW 1984Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochem Biophys Res Commun120885890PubMedCrossRefGoogle Scholar
  13. Green, A, Harvey, R, Thompson, E, Rossor, M 1999Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer’s diseaseNeurosci Lett259133135PubMedCrossRefGoogle Scholar
  14. Grossman, M, Farmer, J, Light, S, Work, M, Moore, P, Van Deerlin, V, Pratico, D, Clark, CM, Coslett, HB, Chatterjee, A, Gee, J, Trojanowski, JQ, Lee, VM 2005Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s diseaseAnn Neurol57721729PubMedCrossRefGoogle Scholar
  15. Haas, C, Selkoe, DJ 1993Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptideCell7510391042CrossRefGoogle Scholar
  16. Hulstaert, F, Blennow, K, Ivanoiu, A, Schoonderwald, HC, Riemenschneider, M, De Deyn, PP, Bancher, C, Cras, P, Wiltfang, J, Mehta, PD, Iqbal, K, Pottel, H, Vanmechelen, E, Vanderstichele, H 1999Improved discrimination of AD-patients using β-amyloid (1-42) and tau levels in CSFNeurology5215551562PubMedGoogle Scholar
  17. Janek, K, Rothemund, S, Gast, K, Beyermann, M, Zipper, J, Fabian, H, Bienert, M, Krause, E 2001Study of the conformational transition of A beta(1-42) using D-amino acid replacement analoguesBiochemistry4054575463PubMedCrossRefGoogle Scholar
  18. Koudinov, AR, Koudinova, NV, Kumar, A, Beavis, RC, Ghiso, J 1996Biochemical characterization of Alzheimer’s soluble amyloid beta protein in human cerebrospinal fluid: association with density lipoproteinsBiochm Biophys Res Commun223592597CrossRefGoogle Scholar
  19. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM 1984Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology34939944PubMedGoogle Scholar
  20. McKhann, GM Albert, MS Grossman, M Miller, B Dickson, D Trojanowski, JQ Work Group on Frontotemporal Dementia and Pick’s Disaese2001Clinical and pathological diagnosis of frontotemporal dementia. Report of the work group on frontotemporal dementia and Pick’s diseaseArch Neurol5818031809PubMedCrossRefGoogle Scholar
  21. Mollenhauer, B, Cepek, L, Bibl, M, Wiltfang, J, Schulz-Schaeffer, W, Ciesielczyk, B, Reiber, H, Neumann, M, Steinacker, P, Poser, S, Trenkwalder, C, Otto, M 2005Tau protein, beta-amyloid(1-42) and S100B protein in cerebrospinal fluid of patients with Dementia with Lewy BodiesDement Cogn Geriatr Disord19164170CrossRefGoogle Scholar
  22. Neary, D, Snowden, JS, Gustafson, L, Passant, U, Stuss, D, Black, S, Freedman, M, Kertesz, A, Robert, PH, Albert, M, Boone, K, Miller, BL, Cummings, J, Benson, DF 1998Frontotemporal lobardegeneration. A consensus on clinical diagnostic criteriaNeurology5115461554PubMedGoogle Scholar
  23. Pitschke, M, Prior, R, Haupt, M, Riesner, D 1998Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer’s patients by fluorescence correlation spectroscopyNat Med4832834PubMedCrossRefGoogle Scholar
  24. Podlisny, MB, Ostaszewski, BL, Squazzo, SL, Koo, EH, Rydell, RE, Teplow, DB, Selkoe, DJ 1995Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell cultureJ Biol Chem27095649570PubMedCrossRefGoogle Scholar
  25. Riemenschneider, M, Wagenpfeil, S, Diehl, J, Lautenschlager, N, Theml, T, Heldmann, B, Drzezga, A, Jahn, T, Förstl, H, Kurz, A 2002Tau and Aβ42 protein in CSF of patients with frontotemporal degenerationNeurology5816221628PubMedGoogle Scholar
  26. Sjögren, M, Minthon, L, Davidson, P, Granerus, AK, Clarberg, A, Vanderstichele, H, Vanmechelen, E, Wallin, A, Blennow, K 2000aCSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal agingJ Neural Transm107563579CrossRefGoogle Scholar
  27. Sjögren, M, Rosgren, L, Minthon, L, Davidson, P, Blennow, K, Wallin, A 2000bCytoskeleton proteins in CSF distinguishfrontotemporal dementia from ADNeurology5419601964Google Scholar
  28. Sjögren, M, Davidsson, P, Tullberg, M, Minthon, L, Wallin, A, Wikkelso, C, Granerus, AK, Vanderstichele, H, Vanmechelen, E, Blennow, K 2001Both total and phosphorylated tau are increased in Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry70624630PubMedCrossRefGoogle Scholar
  29. Verbeek, MM, de Jong, D, Kremer, HPH 2003Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseasesAnn Clin Biochem402540PubMedCrossRefGoogle Scholar
  30. Wiltfang, J, Esselmann, H, Cupers, P, Neumann, M, Kretzschmar, H, Beyermann, M, Schleuder, D, Jahn, H, Rüther, E, Kornhuber, J, Annaert, W, De Strooper, B, Saftig, P 2001Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cellsJ Biol Chem2764264542657PubMedCrossRefGoogle Scholar
  31. Wiltfang, J, Esselmann, H, Bibl, M, Smirnov, A, Otto, M, Paul, S, Schmid, B, Klafki, H-W, Maler, M, Dyrks, T, Bienert, M, Beyermann, M, Rüther, E, Kornhuber, J 2002Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and patients with chronic neuroinflammationJ Neurochem81481496PubMedCrossRefGoogle Scholar
  32. Wiltfang, J, Esselmann, H, Smirnov, A, Bibl, M, Cepek, L, Steinacker, P, Mollenhauer, B, Buerger, K, Hampel, H, Paul, S, Neumann, M, Maler, M, Kornhuber, J, Kretzschmar, HA, Poser, S, Otto, M 2003Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob diseaseAnn Neurol54263267PubMedCrossRefGoogle Scholar
  33. Wiltfang, J, Lewczuk, P, Riederer, P, Grunblatt, E, Hock, C, Scheltens, P, Hampel, H, Vanderstichele, H, Iqbal, K, Galasko, D, Lannfelt, L, Otto, M, Esselmann, H, Henkel, AW, Kornhuber, J, Blennow, K 2005Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementiaWorld J Biol Psychiatry66984PubMedGoogle Scholar
  34. World Medical Organisation1996Declaration of HelsinkiBri Med J31314481449Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • M. Bibl
    • 1
  • B. Mollenhauer
    • 2
  • S. Wolf
    • 2
  • H. Esselmann
    • 3
  • P. Lewczuk
    • 3
  • J. Kornhuber
    • 3
  • J. Wiltfang
    • 3
  1. 1.Department of PsychiatryUniversity of GoettingenGoettingenGermany
  2. 2.Brigham and Women’s Hospital, Center for Neurologic DiseasesHarvard Medical SchoolBostonUSA
  3. 3.Department of Psychiatry and PsychotherapyUniversity of Erlangen-NurembergErlangenGermany

Personalised recommendations